Cancer Therapeutics Program

翻译后摘要：癌症治疗（CT） 癌症治疗（CT）计划的总体目标是开发创新方法， 发现，设计，开发和验证新的抗癌药物和联合治疗方案， 人类癌症为了实现这一使命，该计划主要围绕三个主题：（1）发现和开发 在临床前环境中，新的靶点和检测方法可以补充药物发现的创新方法， 新的药物和联合方案;（2）研究新的和现有的药物的作用机制。 抗癌剂;和（3）进行早期（I/II）临床试验，重点是UPMC Hillman的翻译 癌症中心（HCC）的科学和新药物的发现，以及与国家合作， 癌症研究所（NCI），NCI癌症中心，其他学术中心，合作团体和行业。的 成功地执行这一使命的战略需要整个基本的连续体的参与， 临床前和临床/转化研究。在Adam Brufsky，MD，PhD，Edward Chu博士和Peter Wipf博士，CT有58名成员，代表16个学术部门和5所学校 在匹兹堡大学。CT成员进行以癌症为重点的研究，共获得1490万美元的支持 年度直接成本资金，其中280万美元为NCI资金，200万美元为其他同行评审资金，1010万美元为非 同行评审从2015年到2019年8月，CT成员发表了1，116篇与癌症相关的出版物 其中26%是方案内合作，41%是方案间合作，64%是机构间合作。HCC 支持，包括临床方案和数据管理以及所有共享资源， 加强CTP研究。

Abstract: Cancer Therapeutics (CT) The overarching goal of the Cancer Therapeutics (CT) Program is to develop innovative approaches to discover, design, develop, and validate novel anticancer agents and combination regimens for the treatment of human cancers. To achieve this mission, the Program focuses on three main themes: (1) discover and develop in a pre-clinical setting, novel targets and assays to complement the innovative approaches to drug discovery, novel agents, and combination regimens; (2) investigate the mechanisms of action of new and existing anticancer agents; and (3) conduct early-phase (I/II) clinical trials with a focus on translation of UPMC Hillman Cancer Center (HCC) science and discoveries of novel agents, as well as in partnership with the National Cancer Institute (NCI), NCI cancer centers, other academic centers, cooperative groups, and industry. The strategy for successfully carrying out this mission requires the involvement of the entire continuum of basic, preclinical, and clinical/translational research. Under the leadership of Adam Brufsky, MD, PhD, Edward Chu, MD and Peter Wipf, PhD, CT has 58 members representing 16 academic departments and 5 schools within the University of Pittsburgh. CT members conduct cancer-focused research supported by $14.9M in total annual direct costs funding, of which $2.8M is NCI funding, $2.0M is other peer-reviewed, and $10.1M is non- peer reviewed. From 2015-August 2019, CT members published 1,116 cancer-related publications representing 26% intra-programmatic, 41% inter-programmatic and 64% inter-institutional collaborations. HCC support, including Clinical Protocol and Data Management and all Shared Resources, greatly facilitate and enhance CTP research.